PortalPublikationenUsing proximity extension proteomics assay to identify bioma...

Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction

Standard

Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. / Mohammad, Moman A; Koul, Sasha; Egerstedt, Anna; Smith, J Gustav; Noc, Marko; Lang, Irene; Holzer, Michael; Clemmensen, Peter; Gidlöf, Olof; Metzler, Bernhard; Engstrøm, Thomas; Erlinge, David.

in: SCI REP-UK, Jahrgang 10, Nr. 1, 18663, 01.12.2020.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mohammad, MA, Koul, S, Egerstedt, A, Smith, JG, Noc, M, Lang, I, Holzer, M, Clemmensen, P, Gidlöf, O, Metzler, B, Engstrøm, T & Erlinge, D 2020, 'Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction', SCI REP-UK, Jg. 10, Nr. 1, 18663. https://doi.org/10.1038/s41598-020-75399-6

APA

Mohammad, M. A., Koul, S., Egerstedt, A., Smith, J. G., Noc, M., Lang, I., Holzer, M., Clemmensen, P., Gidlöf, O., Metzler, B., Engstrøm, T., & Erlinge, D. (2020). Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. SCI REP-UK, 10(1), [18663]. https://doi.org/10.1038/s41598-020-75399-6

Vancouver

Mohammad MA, Koul S, Egerstedt A, Smith JG, Noc M, Lang I et al. Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction. SCI REP-UK. 2020 Dez 1;10(1). 18663. https://doi.org/10.1038/s41598-020-75399-6

Bibtex

@article{4ccde5f7d6c541e88fcfb80b42fa806c,
title = "Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction",
abstract = "Plasma concentrations of many cardiovascular and inflammatory proteins are altered after ST-elevation myocardial infarction (STEMI) and may provide prognostic information. We conducted a large-scale proteomic analysis in patients with STEMI, correlating protein levels to infarct size and left ventricular ejection fraction (LVEF) determined with cardiac magnetic resonance imaging. We analysed 131 cardiovascular and inflammatory proteins using a multiplex proximity extension assay and blood samples obtained at baseline, 6, 24, and 96 h from the randomised clinical trial CHILL-MI. Cardiac magnetic resonance imaging data at 4 ± 2 days and 6 months were available as per trial protocol. Using a linear regression model with bootstrap resampling and false discovery rate adjustment we identified five proteins (ST2, interleukin-6, pentraxin-3, interleukin-10, renin, and myoglobin) with elevated values corresponding to larger infarct size or worse LVEF and four proteins (TNF-related apoptosis-inducing ligand, TNF-related activation induced cytokine, interleukin-16, and cystatin B) with values inversely related to LVEF and infarct size, concluding that among 131 circulating inflammatory and cardiovascular proteins in the acute and sub-acute phase of STEMI, nine showed a relationship with infarct size and LVEF post-STEMI, with IL-6 and ST2 exhibiting the strongest association.",
keywords = "Aged, Biomarkers/metabolism, Female, Humans, Male, Middle Aged, Proteomics/methods, ST Elevation Myocardial Infarction/diagnostic imaging",
author = "Mohammad, {Moman A} and Sasha Koul and Anna Egerstedt and Smith, {J Gustav} and Marko Noc and Irene Lang and Michael Holzer and Peter Clemmensen and Olof Gidl{\"o}f and Bernhard Metzler and Thomas Engstr{\o}m and David Erlinge",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41598-020-75399-6",
language = "English",
volume = "10",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction

AU - Mohammad, Moman A

AU - Koul, Sasha

AU - Egerstedt, Anna

AU - Smith, J Gustav

AU - Noc, Marko

AU - Lang, Irene

AU - Holzer, Michael

AU - Clemmensen, Peter

AU - Gidlöf, Olof

AU - Metzler, Bernhard

AU - Engstrøm, Thomas

AU - Erlinge, David

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Plasma concentrations of many cardiovascular and inflammatory proteins are altered after ST-elevation myocardial infarction (STEMI) and may provide prognostic information. We conducted a large-scale proteomic analysis in patients with STEMI, correlating protein levels to infarct size and left ventricular ejection fraction (LVEF) determined with cardiac magnetic resonance imaging. We analysed 131 cardiovascular and inflammatory proteins using a multiplex proximity extension assay and blood samples obtained at baseline, 6, 24, and 96 h from the randomised clinical trial CHILL-MI. Cardiac magnetic resonance imaging data at 4 ± 2 days and 6 months were available as per trial protocol. Using a linear regression model with bootstrap resampling and false discovery rate adjustment we identified five proteins (ST2, interleukin-6, pentraxin-3, interleukin-10, renin, and myoglobin) with elevated values corresponding to larger infarct size or worse LVEF and four proteins (TNF-related apoptosis-inducing ligand, TNF-related activation induced cytokine, interleukin-16, and cystatin B) with values inversely related to LVEF and infarct size, concluding that among 131 circulating inflammatory and cardiovascular proteins in the acute and sub-acute phase of STEMI, nine showed a relationship with infarct size and LVEF post-STEMI, with IL-6 and ST2 exhibiting the strongest association.

AB - Plasma concentrations of many cardiovascular and inflammatory proteins are altered after ST-elevation myocardial infarction (STEMI) and may provide prognostic information. We conducted a large-scale proteomic analysis in patients with STEMI, correlating protein levels to infarct size and left ventricular ejection fraction (LVEF) determined with cardiac magnetic resonance imaging. We analysed 131 cardiovascular and inflammatory proteins using a multiplex proximity extension assay and blood samples obtained at baseline, 6, 24, and 96 h from the randomised clinical trial CHILL-MI. Cardiac magnetic resonance imaging data at 4 ± 2 days and 6 months were available as per trial protocol. Using a linear regression model with bootstrap resampling and false discovery rate adjustment we identified five proteins (ST2, interleukin-6, pentraxin-3, interleukin-10, renin, and myoglobin) with elevated values corresponding to larger infarct size or worse LVEF and four proteins (TNF-related apoptosis-inducing ligand, TNF-related activation induced cytokine, interleukin-16, and cystatin B) with values inversely related to LVEF and infarct size, concluding that among 131 circulating inflammatory and cardiovascular proteins in the acute and sub-acute phase of STEMI, nine showed a relationship with infarct size and LVEF post-STEMI, with IL-6 and ST2 exhibiting the strongest association.

KW - Aged

KW - Biomarkers/metabolism

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Proteomics/methods

KW - ST Elevation Myocardial Infarction/diagnostic imaging

U2 - 10.1038/s41598-020-75399-6

DO - 10.1038/s41598-020-75399-6

M3 - SCORING: Journal article

C2 - 33122738

VL - 10

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

IS - 1

M1 - 18663

ER -